

Enrica Marchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5583906/publications.pdf>

Version: 2024-02-01

34
papers

934
citations

759233

12
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Peripheral T-Cell Lymphoma Involvement of the Central Nervous System: Impact of Novel Therapeutics on Clinical Outcomes</i>. Blood, 2021, 138, 2469-2469.	1.4	3
2	Survival benefit in patients with peripheral Tâ€cell lymphomas after treatments with novel therapies and clinical trials. Hematological Oncology, 2020, 38, 51-58.	1.7	24
3	The rapidly changing landscape in mature Tâ€cell lymphoma (MTCL) biology and management. Ca-A Cancer Journal for Clinicians, 2020, 70, 47-70.	329.8	45
4	Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. Therapeutic Advances in Hematology, 2020, 11, 204062072094734.	2.5	2
5	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia and Lymphoma, 2020, 61, 3014-3017.	1.3	2
6	Generation of pralatrexate resistant Tâ€cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. Genes Chromosomes and Cancer, 2020, 59, 639-651.	2.8	3
7	The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).. Journal of Clinical Oncology, 2020, 38, 8049-8049.	1.6	3
8	The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. Oncotarget, 2020, 11, 1576-1589.	1.8	8
9	A survey of cancer testis antigen (CTA) expression across T-cell lymphoma subtypes.. Journal of Clinical Oncology, 2020, 38, e15246-e15246.	1.6	0
10	Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood, 2019, 134, 1395-1405.	1.4	100
11	New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Review of Hematology, 2019, 12, 137-146.	2.2	12
12	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood, 2018, 131, 397-407.	1.4	109
13	Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. JNCI Cancer Spectrum, 2018, 2, pky038.	2.9	12
14	Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). Blood, 2018, 132, 1002-1002.	1.4	3
15	Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. Hematology/Oncology Clinics of North America, 2017, 31, 359-375.	2.2	9
16	Bone marrow aspirate quality assessment.. Journal of Clinical Oncology, 2017, 35, 76-76.	1.6	1
17	Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate. Blood, 2016, 128, 4149-4149.	1.4	5
18	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of Tâ€cell lymphoma. British Journal of Haematology, 2015, 171, 215-226.	2.5	51

#	ARTICLE	IF	CITATIONS
19	The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in <i>in vivo</i> and <i>in vitro</i> models of aggressive large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2945-2952.	1.3	17
20	Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development. <i>Blood</i> , 2015, 126, 1282-1282.	1.4	3
21	Pralatrexate Pharmacology and Clinical Development. <i>Clinical Cancer Research</i> , 2013, 19, 6657-6661.	7.0	35
22	The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 646-646.	1.4	4
23	Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response. <i>Blood</i> , 2013, 122, 4430-4430.	1.4	0
24	Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. <i>Journal of Cancer Science & Therapy</i> , 2013, 5, 334-342.	1.7	41
25	Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 227-235.	2.5	14
26	Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.. <i>Blood</i> , 2012, 120, 2725-2725.	1.4	0
27	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	1.6	268
28	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2006, 108, 2431-2431.	1.4	6
29	Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.. <i>Blood</i> , 2006, 108, 2462-2462.	1.4	4
30	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. <i>Blood</i> , 2006, 108, 2478-2478.	1.4	0
31	Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. <i>Cancer</i> , 2005, 104, 2437-2441.	4.1	149
32	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2005, 106, 4765-4765.	1.4	0
33	Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 4764-4764.	1.4	1
34	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2005, 106, 4763-4763.	1.4	0